Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation
about
Lipid mediators and allergic diseasesThe role of prostaglandins in allergic lung inflammation and asthmaN-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinantsExploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicityRecent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problemsHuman thromboxane A2 receptor genetic variants: in silico, in vitro and "in platelet" analysisExpression, characterization, and purification of C-terminally hexahistidine-tagged thromboxane A2 receptors.Congenital platelet disorders and understanding of platelet function.Prostanoid receptor antagonists: development strategies and therapeutic applicationsThromboxane and the thromboxane receptor in cardiovascular disease.Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation.Prostanoid receptors: ontogeny and implications in vascular physiology.Genetic variations in human G protein-coupled receptors: implications for drug therapy.EP1- and FP-mediated cross-desensitization of the alpha (alpha) and beta (beta) isoforms of the human thromboxane A2 receptor.Regulation of the tumor suppressor FOXO3 by the thromboxane-A2 receptors in urothelial cancerEndothelium-mediated control of vascular tone: COX-1 and COX-2 products.Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease.The Wilms' tumour suppressor protein WT1 acts as a key transcriptional repressor of the human thromboxane A2 receptor gene in megakaryocytes.Activation of thromboxane receptor alpha induces expression of cyclooxygenase-2 through multiple signaling pathways in A549 human lung adenocarcinoma cells.Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase.Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.The G protein-coupled receptors: pharmacogenetics and disease.Putative role of prostaglandin receptor in intracerebral hemorrhage.An eicosanoid-centric view of atherothrombotic risk factorsCharacterization of endothelial thromboxane receptors in rabbit aortaRole for the thromboxane A2 receptor β-isoform in the pathogenesis of intrauterine growth restriction.Differential regulation of RhoA-mediated signaling by the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor: independent modulation of TPalpha signaling by prostacyclin and nitric oxide.Thromboxane A2 receptor activates a Rho-associated kinase/LKB1/PTEN pathway to attenuate endothelium insulin signaling.Liver kinase B1 is required for thromboxane receptor-dependent nuclear factor-κB activation and inflammatory responses.TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus.Advances in our understanding of the molecular basis of disorders of platelet function.Thromboxane A2 receptor: biology and function of a peculiar receptor that remains resistant for therapeutic targeting.Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke.Congenital defects of platelet function.Harnessing the platelet signaling network to produce an optimal hemostatic response.Antiplatelet therapy: targeting the TxA2 pathway.Interactions between thromboxane A₂, thromboxane/prostaglandin (TP) receptors, and endothelium-derived hyperpolarization.Inhibition of tumor necrosis factor alpha-mediated NFkappaB activation and leukocyte adhesion, with enhanced endothelial apoptosis, by G protein-linked receptor (TP) ligands.Inhibitors of the 5-lipoxygenase pathway activate pannexin1 channels in macrophages via the thromboxane receptor.Up-regulation of Kv7.1 channels in thromboxane A2-induced colonic cancer cell proliferation.
P2860
Q27023936-23CF08BF-7FFC-4C29-97AD-5A9E667574DFQ27024735-FAB661AA-D3E1-4716-A26C-9329CD16468AQ28139403-BC6D35B1-A578-4133-AFD3-9B5ECDF0A836Q28218177-66388B33-6D9F-4BE2-9554-59F153C29FF7Q28218351-E7980E1E-52AB-432D-A314-F2909519DC0CQ28534432-18DBA5CD-B699-4DC6-8CEE-936FF63A4122Q32035935-E96F6CA4-DB99-4445-B107-37B6AD1A6E94Q33411778-3C54769B-0E68-4733-AC12-98CD29BCD4A8Q33485483-3D04355C-2C29-49FF-8E45-6341BCD0FD0CQ33899567-26086636-BD7F-4325-9911-7C59F2312D80Q34389439-842AD7B1-8736-4C4C-BC0D-25BD74F8F2D3Q34407623-F363FE80-00C8-4E4E-BA27-F2DCA3E39394Q34461998-43566E81-51B7-4F99-BC95-C20BD2AF1D0BQ35047084-679F443A-1986-4D2C-A73C-6F7C76B04719Q35244124-5C6B4C38-455F-473D-A848-9A1AA44B9BABQ35376020-EC5490B2-A087-4DF0-A2FB-5AC0242EEB32Q35859255-660D9326-2899-45AD-8C48-9CF14E599FF8Q35889126-5C2C56FB-7E61-44F2-8EEA-06011F163CA0Q36016888-4B56817D-17EF-4453-AEBB-71CBA3FDB5A5Q36058741-BAD631BE-1FB7-4B3D-BCAA-E81BB9FC5FBDQ36166958-A66197D2-7D58-46C6-83D6-3093D9FEB6B0Q36310854-380434E9-6D2D-446D-BA00-8593544E70A2Q36337569-E4DA5EB1-4A83-4A4B-8B3A-AB7DE5AF6D9AQ36952174-CC3A5F34-71B8-401F-978D-9A2497043378Q36975599-AA02BB2A-D16A-4C2A-8A99-3ED58E34B062Q37057328-A434B792-481F-4E24-AB82-E2AD3F968E9CQ37189926-5241F3CF-A63B-45AA-81B8-48D258658920Q37285129-71363DBA-D3B4-489E-A21B-839E2A37624DQ37405459-B2DAA4B5-1E65-4A65-8CB8-0893FF247082Q37782025-2045F6CF-ECBE-48F5-81DC-46F538F8985BQ37903933-FD0FF7F9-05AE-4CC8-A0A1-527A32A9E1CFQ37953820-E98C1BF7-1D6A-4AC5-B72D-64EC89E275FAQ37995534-85D663ED-0FE3-4C50-8263-45E807D1BBD7Q38047367-F778C698-7DBF-40F9-A1D8-E286687F7F11Q38109969-C0A3919E-44AC-4E97-BCE3-4D0F9F36B752Q38172461-63E0777F-FFE4-4868-9EB0-554C5D2709F2Q38182425-A22A770A-DFC0-40D5-9B8D-2C06243B4B6CQ38358934-F0E69315-E217-4BCC-9ADD-D31674B89E5DQ38969864-B8A05728-7184-4C65-A1F6-8129E61618BCQ39101638-E8C01EA9-5175-4863-96A7-4EB796C2CA19
P2860
Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation
description
1996 nî lūn-bûn
@nan
1996 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Two thromboxane A2 receptor is ...... ivity to Arg60 to Leu mutation
@ast
Two thromboxane A2 receptor is ...... ivity to Arg60 to Leu mutation
@en
Two thromboxane A2 receptor is ...... ivity to Arg60 to Leu mutation
@nl
type
label
Two thromboxane A2 receptor is ...... ivity to Arg60 to Leu mutation
@ast
Two thromboxane A2 receptor is ...... ivity to Arg60 to Leu mutation
@en
Two thromboxane A2 receptor is ...... ivity to Arg60 to Leu mutation
@nl
prefLabel
Two thromboxane A2 receptor is ...... ivity to Arg60 to Leu mutation
@ast
Two thromboxane A2 receptor is ...... ivity to Arg60 to Leu mutation
@en
Two thromboxane A2 receptor is ...... ivity to Arg60 to Leu mutation
@nl
P2093
P2860
P3181
P356
P1476
Two thromboxane A2 receptor is ...... ivity to Arg60 to Leu mutation
@en
P2093
P2860
P304
P3181
P356
10.1172/JCI118518
P407
P577
1996-02-01T00:00:00Z